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Abstract
Background: Drugs can influence the whole biological system by targeting interaction reactions. The existence of
interactions between drugs and network reactions suggests a potential way to discover targets. The in silico
prediction of potential interactions between drugs and target proteins is of core importance for the identification
of new drugs or novel targets for existing drugs. However, only a tiny portion of drug-targets in current datasets
are validated interactions. This motivates the need for developing computational methods that predict true
interaction pairs with high accuracy. Currently, network pharmacology has used in identifying potential drug
targets to predicting the spread of drug activity and greatly contributed toward the analysis of biological systems
on a much larger scale than ever before.
Methods: In this article, we present a computational method to predict targets for rhein by exploring drug-
reaction interactions. We have implemented a computational platform that integrates pathway, protein-protein
interaction, differentially expressed genome and literature mining data to result in comprehensive networks for
drug-target interaction. We used Cytoscape software for prediction rhein-target interactions, to facilitate the drug
discovery pipeline.
Results: Results showed that 3 differentially expressed genes confirmed by Cytoscape as the central nodes of the
complicated interaction network (99 nodes, 153 edges). Of note, we further observed that the identified targets
were found to encompass a variety of biological processes related to immunity, cellular apoptosis, transport, signal
transduction, cell growth and proliferation and metabolism.
Conclusions: Our findings demonstrate that network pharmacology can not only speed the wide identification of
drug targets but also find new applications for the existing drugs. It also implies the significant contribution of
network pharmacology to predict drug targets.
Background
Developing a new drug is an expensive and time-con-
suming process that is subject to a variety of regulations
such as drug toxicity monitoring and therapeutic effi-
cacy. Lengthy development procedures and the high risk
of unexpected side-effects in advanced-stage clinical
trials reduce the ability of the drug development process
to be innovative. However, the organization of our
rapidly growing knowledge on diseases, disease-related
genes, drug targets and their structures, and drugs and
their chemical structures gives us another exciting way
to discover novel areas of drug development. Several
networks have recently been constructed to help drug
discovery [1]. Meanwhile, finding the potential applica-
tion in other therapeutic categories of drugs by predict-
ing their targets is an efficient and time-saving method
in drug discovery [2]. Additionally, predicting interac-
tions between drugs and target proteins can help deci-
pher the underlying biological mechanisms. Therefore,
there is a strong incentive to develop powerful statistical
methods that are capable of detecting these potential
drug-protein interactions. Various methods have been
proposed to address the drug-target prediction pro-
blems. One common method is to predict the drugs
interacting with a single given protein based on the che-
mical structure similarity in a classic classification fra-
mework. Nevertheless, all the methods did not utilize a
wealth of information to assist prediction.
* Correspondence: xijunwangls@126.com
1National TCM Key Lab of Serum Pharmacochemistry, Heilongjiang University
of Chinese Medicine, Heping Road 24, Harbin 150040, China
Full list of author information is available at the end of the article
Zhang et al. BMC Systems Biology 2012, 6:20
http://www.biomedcentral.com/1752-0509/6/20
© 2012 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

































Despite the dramatic increase of global spending on
drug discovery and development, the approval rate for
new drugs is declining, due chiefly to toxicity and unde-
sirable side effects. Simultaneously, the growth of avail-
able biomedical data in the postgenomic era has
provided fresh insight into the nature of drug-target
pathways. This stagnation in drug approval can be over-
come by the novel concept of network pharmacology,
which is built on the fundamental concept that drugs
modulate the multiple targets. Network pharmacology
can be studied with molecular networks that integrate
multidisciplinary concepts including cheminformatics,
bioinformatics, and systems biology. Network analysis
has become a cornerstone of fields as diverse as systems
biology. Many studies have successfully reported inter-
esting biological findings from these networks, including
the relationships between various statistical properties of
a gene and its function at the molecular level based on
networks [3]. Network pharmacology can make an
impact at several points in the drug-development pro-
cess: target identification, lead discovery and optimiza-
tion, mode of action, preclinical efficacy and safety
assessment. Therefore, it could facilitate the systematic
characterisation of drug targets, thereby helping to
reduce the typically high attrition rates in discovery pro-
jects. Various approaches have been proposed for this
task such as Bayesian Networks, models based on infor-
mation theory, regression based models, and differential
equation models [4,5].
Software to integrate and analyse the interactions and
their attributes plays an increasingly important role. The
most widely used open source network visualization
workbench is Cytoscape, a popular bioinformatics pack-
age for biological network visualization and data integra-
tion, for screening the central nodes of the network,
exploiting functional study of the central node genes [6].
Cytoscape software, a web-based network visualization
tool, is an open-source software platform for visualizing
molecular interaction networks and integrating these
interactions with gene expression profiles and other
functional genomics data. Data from various sources can
be imported into this tool to build networks, and to
highlight specific node or edge features. By providing
platforms to integrate data with molecular interaction
networks, researchers can more rapidly begin interpreta-
tion of large data sets collected for a system of interest.
Cytoscape’s main functionality is focused on the con-
struction of networks. Currently, the network model is
based on genes, proteins and functional relationships
between them such as protein-protein, protein-dna reg-
ulatory interactions and gene-protein coding relation-
ship [7].
Rhubarb, one of popular traditional Chinese herbal
medicine, has been widely used for the treatment of
diseases in traditional Chinese medicine. Rhein (Figure
1) is one of the most bioactive components from rhu-
barb. Earlier studies have identified rhein as a potent
inhibitor of hepatic fibrosis induced by carbon tetra-
chloride, which is capable of reducing SMA expression,
collagen synthesis and deposition in TGF-stimulated
hepatic stellate cells. A recent study showed that rhein
contributes to induce apoptosis of human cancer,
including lung adenocarcinoma A549, myelogenous leu-
kemia HL-60, lung squamous carcinoma CH27, cervical
carcinoma HeLa cells, neuroblastoma IMR-32, bladder
cancer T24, and hepatoma HepG2 cells [8]. It can inhi-
bits cellular proliferation, induces apoptosis, and pre-
vents metastasis through activation of tyrosine kinases,
phosphoinositol 3-kinase, protein kinase C, NF-kappa B,
and mitogen-activated protein kinase signaling cascades.
It has antitumor properties through the p53 and its
downstream p21 pathway, also reduce tumor size, pro-
long survival, decrease incidence of tumor invasion and
neovascularization. Interestingly, rhein blocks the uptake
of glucose in tumor cells, causing changes in membrane
associated functions to trigger cell death. Although
these results suggest that rhein may be a potent antitu-
mor drug, and its therapeutic mechanism were still
completely unclear.
Reconstructing networks of biological system entities
such as genes, transcription factors, proteins, com-
pounds and other regulatory molecules are very impor-
tant for understanding the biological processes.
Identifying drug targets is a critical step in network
pharmacology. Recent years network pharmacology has
influenced all areas of life sciences including that of
drug mechanism and development, new target discovery
[9]. Efficient identification of drug targets is one of
major challenges for drug discovery and drug develop-
ment. Computational integration of different knowledge
Figure 1 Chemical structure of rhein . ChemSpider ID: 9762;
Systematic name: 4,5-Dihydroxy-9,10-dioxo-9,10-dihydro-2-
anthracenecarboxylic acid; Molecular Formula: C15H8O6; Mass:
284.032074 Da.
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sources is a more effective approach and wealth of Sys-
Biomics data provides unprecedent opportunities for
drug target identification [10]. Although a number of
computational approaches have been developed to inte-
grate data from multiple sources for the purpose of pre-
dicting or prioritizing candidate disease genes, relatively
few of them focus on identifying or ranking drug tar-
gets. To address this deficit, we construct a biological
network to provide a global view of drug interactions
and prioritize drug candidate targets. We demonstrate
the applicability of integrative network pharmacology
approaches to identify potential drug targets and candi-
date genes by employing information extracted from
public databases. In the present investigation, we give an
illustrative example to show that the potential drug tar-
get identification problem can be solved effectively by
our method, which may become an effective strategy for
the discovery of new drugs.
Methods
Interaction information was retrieved from NCBI’s
Entrez Gene in December 16, 2011. Genes/proteins
molecular function, biological processes and cellular
component is imported from the Gene Ontology pro-
ject; while information on biochemical pathways is
taken from KEGG. Additional information includes links
to databases, such as Reactome, BioCyc, NCI Nature
PID, DIP, BIND, HPRD, BioGRID, MINT, and Intact,
which represent the major repositories of interacions
from multiple organisms for further bioinformatics ana-
lysis. The associations between the diseases and genes
were from the OMIM (Online Mendelian Inheritance in
Man, http://www.ncbi.nlm.nih.gov/omim). The most
stable one is the Entrez GeneID, which is the unique
identifier for a gene in NCBI’s Entrez Gene database.
Cytoscape has being developed for reconstruction and
visualization of networks. Nodes (represented as circles)
in the interactome correspond to genes, and edges (con-
necting lines) represent documented interactions. Cytos-
cape is a desktop Java application and source code for
Cytoscape 2.8 are available for download from http://
cytoscape.org. Its default annotations are parsed from
the GO information available from NCBI http://www.
ncbi.nlm.nih.gov/Ftp/.
Results
Module annotation and visualization
Functional annotation for predicted bindingtargets in
our models by looking for enriched terms from multiple
functional databases. Since modules often show strong
functional coherence, the diverse set of annotations pro-
vide a complementary overview of module function. For
pathway visualization and analysis of networks, we used
open-source Cytoscape version 2.8 software. In
Cytoscape, networks are represented as graphs where
the nodes are the entities (e.g. genes, proteins) and the
edges their interactions (e.g. reactions). For the visuali-
zation in the context of biological networks, we devel-
oped the different node attribute files and visual style
files that can easily be imported into Cytoscape. This
benchmark was run on a standard desktop computer (4
GHz Pentium intel with 2 GB of memory running Win-
dows XP).
Constructing regulatory network
We used Cytoscape version 2.8 to model the signaling
network. Taking the closely-connected and co-expressed
differentially expressed genes, for the network shown in
Figure 2 and 3, with 99 nodes and 153 edges. Four of
them are significant frequencies and are likely to be
responsible for driving the initiation, progression, or
maintenance of disease. We find that 3 genes considered
linked because they had close relationship and suggested
as novel susceptibility genes using the Cytoscape visuali-
zation software. The 3 perturbed genes in the network
that has strong connections to the genes. This is indi-
cated by the thick edges between these nodes.
Predicting drug targets
Another issue clearly meriting further study is the per-
formance of our proposed method in identifying drug
targets. We believe these results are indicative of the
multi-level nature of key perturbations, where direct
interactions often take place at the protein and/or meta-
bolite level, and therefore do necessarily affect expres-
sion level of the encoding genes. Main pathway
information, 3 targets are observed in the Cytoscape-
based network with significant P-values. Figure 4
denotes the identification of novel molecular targets
using network analysis. These closely connected and
coexpressed differentially expressed genes and proteins
in the networks are regarded as the signatures of the
rhein underlying targets. Regulatory sub-network of
rhein targets through network pharmacology was con-
structed, and shown in Figure 5. The detail information
of the novel molecular targets were shown in additional
Table 1.
Discussion
Network pharmacology approach seeks to comprehend
the complexity of organisms by combining many differ-
ent kinds of data (protein-protein and protein-DNA
interactions, protein modifications, biochemistry, etc.) to
create predictive models. In the era of SysBiomics, the
focus on understanding complex organisms is shifting
from studying individual genes and proteins towards the
relationships between them [11,12]. These relationships
are usually expressed in terms of various kinds of
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Figure 2 Solid map on huge interactome of rhein-targets networks, built and visualized with Cytoscape. Edges: interactions. Nodes:
specific proteins or genes. Central nodes (Yellow) of the interaction network were used to illustrate the gene expression obtained and
represents significant change in expression. The connections between molecules show molecular interactions identified in the interactome. Gene
expression illustrated in colored nodes was selected with a p < 0.05 value.
Figure 3 Illustration and visualization of the interactome network (Circle Layout). Drugs and proteins are linked as per the known drug-
target network. Discrete network map with a customized visual Cytoscape Web style. Yellow nodes refer to the significant ontologies of the
target. This subnetwork represents a coregulated unit containing 99 nodes and 153 edges.
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biological networks that are the focus of many func-
tional genomics studies. Systems biology is characterized
by a focus on interaction networks–the biomolecules
involved in a particular biological system or process, as
well as the relationships between these components.
Network pharmacology is used for visualizing and
understanding these interactions, interpreting high-
throughput experimental data, generating hypotheses
and sharing results [13]. These diagrams can be difficult
for a user to explore with currently available network
display tools–the networks are often too large, on the
order of thousands of nodes, and many tools do not
provide biological context to the diagram. The increas-
ing complexity of functional genomics data drives the
development of methods and tools for data integration
and visualization [14].
Interactions network models are crucially important
for disease processes [15]. Many of the important prop-
erties of biological systems emerge as a result of the
interactions among genes and among their protein pro-
ducts. Genes and the proteins they encode participate in
gene-gene, gene-protein, and protein-protein interac-
tions to mediate a wide variety of biological processes.
Molecular interaction networks can be efficiently studied
using network visualization software. Cytoscape that can
generate a putative protein-protein interaction network
for target genomes, make the creation of protein-protein
interaction network predicting tools possible. Its central
organizing principle is a network graph, with biological
entities (e.g. genes, proteins) represented as nodes and
biological interactions represented as edges between
nodes. Data are integrated with the network using attri-
butes, which map nodes or edges to specific data values
such as gene expression levels or protein functions.
Taken together, these features provide a mechanism for
expressing relationships between sets of data while
simultaneously visualizing the integrated results.
In this study, we applied Cytoscape to explore targets
expression data in the context of biological network
information. Of note, Cytoscape successfully provided us
with valuable clues for identification of drug-target
interactions on a large scale. Rhein, a classic natural
product, has been efficiently used for cancer relief in
Asia, although its mechanism remains unclear. A
Figure 4 Identification of novel molecular targets using network analysis. A: MMP2; B: MMP9; C: TNF.
Figure 5 Regulatory sub-network of differentially expressed
TNF of rhein through network pharmacology.
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promising approach in drug target discovery involves
the integration of available metabolites data through
mathematical modeling and data mining. Significant
work has been done on drug discovery, however, few
papers were discussed with the interaction network.
This study was designed to further elucidate the under-
lying mechanism of rhein from the network pharmacol-
ogy. Of note, 3 differentially expressed genes were
observed. The characteristic functions of the differen-
tially expressed proteins were based on biological pro-
cesses such as immunity, cellular apoptosis, transport,
signal transduction, cell growth and proliferation and
metabolism. The detection of these proteins with dis-
tinct regulatory patterns provides evidence that novel
biomarkers are actively involved in multifunctional path-
ways. Proteins of the matrix metalloproteinase (MMP2
and 9) family are involved in the breakdown of extracel-
lular matrix in normal physiological processes, such as
reproduction, and tissue remodeling, as well as in dis-
ease processes, such as arthritis and metastasis. Most
MMP’s are secreted as inactive proproteins which are
activated when cleaved by extracellular proteinases. This
gene encodes an enzyme which degrades type IV col-
lagen, the major structural component of basement
membranes. The enzyme plays a role in endometrial
menstrual breakdown, regulation of vascularization and
the inflammatory response. Tumor necrosis factor
(TNF) encodes a multifunctional proinflammatory cyto-
kine that belongs to the tumor necrosis factor superfam-
ily. This cytokine is mainly secreted by macrophages. It
can bind to, and thus functions through its receptors
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cyto-
kine is involved in the regulation of a wide spectrum of
biological processes including cell proliferation, differen-
tiation, apoptosis, lipid metabolism, and coagulation.
This cytokine has been implicated in a variety of dis-
eases, including autoimmune diseases, insulin resistance,
and cancer.
The dominant paradigm in drug discovery is the con-
cept of designing maximally selective drug targets. How-
ever, many effective drugs act via modulation of
multitargets rather than single targets. Advances in sys-
tems biology are revealing that integrated network biol-
ogy holds the promise of expanding the current
opportunity space for drug targets [16]. Identification of
drug targets is one of the major tasks in drug discovery
[17]. Under these circumstances, there is an urgent need
to integrate phenotypic and chemical indexes together
and develop new methods to predict drug-target interac-
tions on a large scale. With the development of systems
biology and the emergence of network pharmacology
approach, it has been possible to integrate multidimen-
sional information and heterogeneous data in drug stu-
dies [18]. Our method benefits from current knowledge
such as the known drug-target interactions, more
importantly, extends the candidate target proteins to a
genome-wide scale, which greatly enlarges the number
of known targets. Together with known drug-target
interactions, such information makes it possible to relate
pharmacological space with genomic space. Thus, we
believe that combining the integration of multi-dimen-
sional information in pharmacological space and
Table 1 Information of the novel molecular targets
GeneID Entry Gene name Disease Pathway
4313 MMP2 Cancer GnRH signaling pathway
Choriocarcinoma Leukocyte transendothelial migration
Torg-Winchester syndrome Pathways in cancer
4318 MMP9 Penile cancer Pathways in cancer
Metaphyseal dysplasias Leukocyte transendothelial migration
Transcriptional misregulation in cancer
7124 TNF Asthma MAPK signaling pathway
Systemic lupus erythematosus Cytokine-cytokine receptor interaction
Malaria Natural killer cell mediated cytotoxicity
Pertussis NOD-like receptor signaling pathway
Type I, II diabetes mellitus Toll-like receptor signaling pathway
Alzheimer’s disease RIG-I-like receptor signaling pathway
Amoebiasis Natural killer cell mediated cytotoxicity
Tuberculosis T cell receptor signaling pathway
Hepatitis C Fc epsilon RI signaling pathway
Influenza A Apoptosis
HTLV-I infection TGF-beta signaling pathway
Herpes simplex infection Natural killer cell mediated cytotoxicity
Cardiovascular Diseases; Hematopoietic cell lineage
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genomic space gains advantages in target identification
information could help to generate further drug discov-
ery. Drug target is a key molecule involved in a signaling
pathway that is specific to a disease condition [19-23].
Drugs can be designed to modify the functioning of the
pathway in the diseased state by inhibiting a key mole-
cule, or to enhance the normal pathway by promoting
specific molecules that may have been affected in the
diseased state and can influence the whole biological
system by targets. Identification of drug target is the
essential first step in new drug discovery and develop-
ment [24]. Discovery of drug targets through network
pharmacology analysis promises to be a useful and novel
approach in this direction. Of note, we have character-
ized 3 specific genes relevant for drug target discovery
and found drug-target interaction networks involve
receptors, neurotransmitter, enzymes, signal transduc-
tion. These results suggest that network analysis can be
an effective means to prioritize drug target interactions
for further study.
Conclusions
System networks that are a central paradigm in biology
will help us identifying new drug targets which in turn
will generate more in-depth understanding of the
mechanism of diseases. Network-based pharmacology is
emerging as an important paradigm for analysis of bio-
logical systems. In this paper, we presented a integrated
approach to predict targets for rhein by exploring net-
work pharmacology, integrating information from che-
mical space, genomic space and drug-protein interaction
network space. Furthermore, network interactions
allowed us to confirm some strongly-predicted drug-tar-
get interactions on the data sets obtained using our
method. Analyzing the topology of the network, we have
detected 3 potential drug targets and predicted the
major interactome by using validated Cyoscape method.
The identified targets were found to encompass a variety
of biological processes related to immunity, cellular
apoptosis, transport, signal transduction, cell growth and
proliferation and metabolism. Perturbed proteins tend
to be highly coexpressed and functionally coherent and
we have used this property for predicting drug targets
and associating novel functions to drug. The findings
demonstrate that the network target-based methods are
of importance for elucidating the inter-relationship
between complex diseases and drug interventions
through the network target paradigm estimating.
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